Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: A prospective study

Journal of Clinical Psychiatry

Volumn 59, Issue 10, 1998, Pages 521-527

  Lindenmayer, Jean Pierre ^a   Iskander, Adel ^a   Park, Mohan ^a   Apergi, Fotini Sonia ^a   Czobor, Pal ^b   Smith, Robert ^a   Allen, David ^b  

^a MANHATTAN PSYCHIATRIC CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG RESPONSE; HUMAN; MENTAL DISEASE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHIATRIC DIAGNOSIS; RATING SCALE; REFRACTORY PERIOD; SCHIZOPHRENIA; TREATMENT PLANNING;

EID: 0031785149     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n1005     Document Type: Article

References (28)

1. Kane J, Honigfeld G, Singer J, et al, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
2. Alvir JM, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994;55(suppl 1B):137-138
3. Bondolfi G, Bauman P, Patris M, et al. A randomized double-blind trial of risperidone versus clozapine for treatment resistant chronic schizophrenia. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 24, 1995; Miami, Fla. Abstract NR485:185
4. Klieser E, Lehman E, Kinzler E, et al. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995;15(suppl 1):45S-51S
5. Daniel DG, Goldberg TE, Weinberger DR, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996;153:417-419
6. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992; 160(suppl 17):46-53
7. Goldberg TE, Greenberg RD, Griffin SJ, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993;162:43-48
8. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-712
9. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long term effects of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-725
10. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994;55(9, suppl B):82-87
11. Daniel DG. Comparison of risperidone and clozapine in clinical and cognitive functions in psychotic disorders. Biol Psychiatry 1994;35:667
12. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 1996;41(8, suppl 2):S35-S40
13. Green M, Marshall B, Wirshing W, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804
14. Kay SR, Fiszbein A, Opter LA. The Positive and Negative Syndrome Scales (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
15. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
16. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;45(suppl 212):11-19
17. Psychopharmacology Research Branch, National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-537
18. Golden JC. Stroop Color and Word Test. Chicago, Ill: Stoelting; 1978
19. Gronwall DMA. Paced Auditory Serial-Addition Task: a measure of recovery from concussion. Percept Mot Skills 1977;44:367-373
20. Wechsler D. WAIS-R Manual. New York, NY: Psychological Corporation; 1981
21. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol 1991;5:125-142
22. Sahakian BJ, Morris RG, Evenden JL, et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain 1988;3:695-718
23. Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia 1966;5:135-140
24. Reitan RM. Validity of the Trail Making test as an indication of organic brain damage. Percept Mot Skills 1958;8:271-276
25. Kay SR. Provisional norms and percentile ranks for the PANSS. In: Positive and Negative Syndromes in Schizophrenia. New York, NY: Bruner/Mazel; 1991:229
26. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five factor model of schizophrenia: initial validation. J Nerv Ment Dis 1994;182:631-638
27. Lindenmayer J-P, Apergi F-S. The relationship between clozapine plasma levels and clinical response. Psychiatr Ann 1996;26:406-412
28. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989;50:329-338